Robin Lachmann

11.1k total citations · 4 hit papers
129 papers, 6.3k citations indexed

About

Robin Lachmann is a scholar working on Physiology, Molecular Biology and Epidemiology. According to data from OpenAlex, Robin Lachmann has authored 129 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Physiology, 38 papers in Molecular Biology and 37 papers in Epidemiology. Recurrent topics in Robin Lachmann's work include Lysosomal Storage Disorders Research (65 papers), Metabolism and Genetic Disorders (22 papers) and Trypanosoma species research and implications (22 papers). Robin Lachmann is often cited by papers focused on Lysosomal Storage Disorders Research (65 papers), Metabolism and Genetic Disorders (22 papers) and Trypanosoma species research and implications (22 papers). Robin Lachmann collaborates with scholars based in United Kingdom, Netherlands and Germany. Robin Lachmann's co-authors include Frances M. Platt, Elaine Murphy, Timothy M. Cox, Derralynn Hughes, Stacey Efstathiou, Raymond A. Dwek, Terry D. Butters, Atul Mehta, Perry Elliott and Johannes M. F. G. Aerts and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Brain.

In The Last Decade

Robin Lachmann

120 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

2010 692 citations Frederick J. Raal, Raúl D. Santos et al. The Lancet profile →
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

2000 592 citations Timothy M. Cox, Robin Lachmann et al. The Lancet profile →
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

2009 509 citations José Brás, Emma Deas et al. Brain profile →
Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping

2013 365 citations Daniel Sado, Robin Lachmann et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Lachmann United Kingdom	43	3.4k	1.8k	1.5k	1.2k	1.0k	129	6.3k
Atul Mehta United Kingdom	57	7.2k 2.1×	2.6k 1.4×	3.3k 2.2×	2.5k 2.2×	1.9k 1.9×	237	11.1k
Dominique P. Germain France	49	7.7k 2.3×	1.7k 1.0×	3.6k 2.4×	2.3k 2.0×	2.2k 2.2×	218	10.0k
Nina Raben United States	52	4.1k 1.2×	3.1k 1.7×	2.7k 1.8×	1000 0.9×	729 0.7×	115	8.1k
Gregory M. Pastores United States	50	7.5k 2.2×	2.2k 1.2×	3.1k 2.1×	2.8k 2.4×	2.3k 2.3×	204	8.8k
Nathalie Guffon France	35	5.2k 1.5×	1.2k 0.7×	2.4k 1.6×	914 0.8×	1.1k 1.1×	138	6.5k
M. Elleder Czechia	32	2.7k 0.8×	1.4k 0.8×	885 0.6×	1.1k 0.9×	570 0.6×	194	4.1k
Yoshikatsu Eto Japan	38	2.1k 0.6×	1.7k 1.0×	764 0.5×	673 0.6×	532 0.5×	225	4.5k
Vassili Valayannopoulos France	39	2.0k 0.6×	1.5k 0.8×	834 0.6×	412 0.4×	292 0.3×	125	4.7k
Emil Kakkis United States	37	3.5k 1.0×	1.1k 0.6×	1.7k 1.1×	598 0.5×	623 0.6×	73	5.0k
Toya Ohashi Japan	38	2.0k 0.6×	2.0k 1.1×	870 0.6×	676 0.6×	494 0.5×	198	4.6k

Countries citing papers authored by Robin Lachmann

Since Specialization

Citations

This map shows the geographic impact of Robin Lachmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Lachmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Lachmann more than expected).

Fields of papers citing papers by Robin Lachmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Lachmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Lachmann. The network helps show where Robin Lachmann may publish in the future.

Co-authorship network of co-authors of Robin Lachmann

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Lachmann. A scholar is included among the top collaborators of Robin Lachmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Lachmann. Robin Lachmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Walton, Matthew, Mark Corbett, Sarah J Nevitt, et al.. (2025). The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS. The European Journal of Health Economics.

Lachmann, Robin, Elaine Murphy, Gavin Clunie, et al.. (2025). Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK. Calcified Tissue International. 116(1). 122–122.

Lin, Siying, Anthony G. Robson, Dorothy Thompson, et al.. (2024). Non‐syndromic retinal dystrophy associated with biallelic variation of SUMF1 and reduced leukocyte sulfatase activity. Clinical Genetics. 106(4). 505–511. 1 indexed citations

Monda, Emanuele, Athanasios Bakalakos, Robin Lachmann, et al.. (2024). Incidence and risk factors for development of left ventricular hypertrophy in Fabry disease. Heart. 110(12). 846–853. 6 indexed citations

Lachmann, Robin, et al.. (2023). Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults. Orphanet Journal of Rare Diseases. 18(1). 94–94. 10 indexed citations

Hennis, P. J., Elaine Murphy, Rick I. Meijer, et al.. (2022). Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study. Orphanet Journal of Rare Diseases. 17(1). 28–28. 4 indexed citations

Moinuddin, Md, et al.. (2021). Long‐term cognitive and psychosocial outcomes in adults with phenylketonuria. Journal of Inherited Metabolic Disease. 44(6). 1353–1368. 35 indexed citations

Sirrs, Sandra, Marie‐Françoise Arthus, Daniel G. Bichet, et al.. (2020). Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products. Value in Health. 24(2). 268–273. 5 indexed citations

Kamenický, Peter, Robin Lachmann, Martine Cohen‐Solal, et al.. (2018). A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF BUROSUMAB, AN ANTI-FGF23 ANTIBODY, IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH). Osteoporosis International. 29. 1 indexed citations

10.

Nordin, Sabrina, Rebecca Kozor, Katia Menacho, et al.. (2018). Proposed Stages of Myocardial Phenotype Development in Fabry Disease. JACC. Cardiovascular imaging. 12(8). 1673–1683. 104 indexed citations

11.

Lachmann, Robin, et al.. (2018). Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report. Journal of Medical Case Reports. 12(1). 134–134. 15 indexed citations

12.

Capelle, Carine I. van, Jan C. van der Meijden, Johanna M. P. van den Hout, et al.. (2016). Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet Journal of Rare Diseases. 11(1). 65–65. 47 indexed citations

13.

Smith, Matthew D., Katarina Ivana Tudor, Zoë Fox, et al.. (2015). Bladder and Bowel Dysfunction Is Common in Both Men and Women with Mutation of the ABCD1 Gene for X-Linked Adrenoleukodystrophy. JIMD Reports. 22. 77–83. 13 indexed citations

14.

Guest, Julian F., et al.. (2012). Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine‐restricted diet. Journal of Intellectual Disability Research. 57(6). 567–579. 29 indexed citations

15.

Lachmann, Robin. (2011). Enzyme replacement therapy for lysosomal storage diseases. Current Opinion in Pediatrics. 23(6). 588–593. 108 indexed citations

16.

O’Mahony, Constantinos, Caroline Coats, Margherita Calcagnino, et al.. (2011). Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. EP Europace. 13(12). 1781–1788. 61 indexed citations

17.

Raal, Frederick J., Raúl D. Santos, Dirk Blom, et al.. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet. 375(9719). 998–1006. 692 indexed citations breakdown →

18.

Brás, José, Emma Deas, Sean S. O’Sullivan, et al.. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 132(7). 1783–1794. 509 indexed citations breakdown →

19.

Lachmann, Robin, Nathan Wright, Michael F. Coleman, et al.. (2006). Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat. Journal of Inherited Metabolic Disease. 29. 130–130. 4 indexed citations

20.

Lachmann, Robin. (2004). Herpes simplex virus‐based vectors. International Journal of Experimental Pathology. 85(4). 177–190. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact